What is HC Wainwright’s Estimate for SXTP Q2 Earnings?

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP – Free Report) – Equities research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for 60 Degrees Pharmaceuticals in a research report issued on Wednesday, May 20th. HC Wainwright analyst M. Keller now expects that the company will post earnings per share of ($0.58) for the quarter, down from their prior estimate of ($0.53). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.84) EPS and FY2026 earnings at ($3.14) EPS.

Get 60 Degrees Pharmaceuticals alerts:

60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.52). The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.44 million.

Other equities analysts have also issued research reports about the stock. Wall Street Zen lowered shares of 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, April 12th. Ascendiant Capital Markets lowered their price objective on shares of 60 Degrees Pharmaceuticals from $11.20 to $4.20 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $14.10.

Read Our Latest Report on 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Price Performance

Shares of 60 Degrees Pharmaceuticals stock opened at $1.49 on Friday. The firm has a market cap of $3.96 million, a PE ratio of -0.11 and a beta of 2.69. 60 Degrees Pharmaceuticals has a 1 year low of $1.29 and a 1 year high of $14.68. The stock has a fifty day moving average price of $1.77 and a 200-day moving average price of $2.86.

About 60 Degrees Pharmaceuticals

(Get Free Report)

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.

Featured Stories

• Five stocks we like better than 60 Degrees Pharmaceuticals
• Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
• As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
• Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
• The Silver Lining of Last Week’s Hims & Hers Earnings Miss

Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.